CN1582925A - Powder injection of benzimidazole hydrochloride, etc. for animals - Google Patents
Powder injection of benzimidazole hydrochloride, etc. for animals Download PDFInfo
- Publication number
- CN1582925A CN1582925A CN 200410006428 CN200410006428A CN1582925A CN 1582925 A CN1582925 A CN 1582925A CN 200410006428 CN200410006428 CN 200410006428 CN 200410006428 A CN200410006428 A CN 200410006428A CN 1582925 A CN1582925 A CN 1582925A
- Authority
- CN
- China
- Prior art keywords
- albendazole
- injectable powder
- injection
- powder
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
A powder injection of benzimidazole hydrochloride antiparasitic is characterized in that: when using, hydrochloric acid albendazole sulfoxide or other hydrochloride benzimidazole drugs is dissolved or dispersed by solvent, and then injects the solution. Preferably, the solvent for melting the hydrochloride albendazole sulfoxide is water or water/1, 2-propanediol or 1, 2-propanediol/formal glycerine; and the proper dissolvent for melting hydrochloride oxfendazole is 1, 2-propanediol or 1, 2-propanediol/formal glycerine. The powder injection can be used for preparing high concentration drug solution and is better than water injection having been sold in market, therefore, it is fit for preventing parasitosis. The injection can be conveniently transported and stored, and the administration manner (e.g. drench or injection) and concentration of the injection can be regulated according to different use. The injection can combine with macrolide drug and/or levamisole hydrochloride to form compound injection, administrated by injection or oral.
Description
Technical field
The present invention relates to a kind of anthelmintic injection for animals, specifically: the present invention is prepared into hydrochlorate with albendazole, albendazole sulfoxide, Phenbendasol or oxfendazole, further is prepared into powder needle injection or veterinary compound anti-parasitic powder needle injection.
Background technology
The Albendazole oxide monohydrochloride aqueous injection generally can only be prepared into 10% concentration, as excessive concentration, easily separates out between storage period; And the aqueous injection pH value is too low, and is about 0.6～0.9, when pH is too high, deposits certain hour, and active ingredient can be separated out.PH exceeded the acceptable pH scope of animal body, so the aqueous injection zest was bigger at 0.6～0.9 o'clock.
There is not storage period preparation instability problem in injectable powder matching while using system, and can prepares highly concentrated solution, and concentration can reach 30% or higher.Thereby significantly reduced volume injected, the albendazole sulfoxide injection that has therefore alleviated because of the injection low concentration needs to inject pain and the inconvenience that larger volume brings to the injection site.This point is used very significant beyond doubt for large animal (as cattle, horse).Time spent now joins, can not will the pH value of solution transfer too low, pH 1.5～3.0 can, therefore, the deficiency that has overcome the aqueous injection this respect of part.It is the most suitable that this agent is used for large animal anthelmintics such as pig, cattle, sheep.
Albendazole oxide monohydrochloride and Macrolide anthelmintic drug can't be combined into the liquid compound preparation, because the existence of Albendazole oxide monohydrochloride makes preparation pH too low (less than 1.5), have exceeded the pH stability range of Macrolide anthelmintic drug.Albendazole oxide monohydrochloride and Macrolide anthelmintic drug are combined into the compound recipe injectable powder, preparation stabilization, storage life can reach more than 2 years, and easy to use, excellent.
The preparation method of the hydrochloric acid benzimidazole medicine that the present invention is used is as follows: albendazole (Albendazole) or albendazole sulfoxide (Albendazole oxide) or benzene sulfur imidazoles (Fenbendazole) or oxfendazole (Oxfendazole) are mixed (mole such as the addition of hydrochloric acid and benzimidazole medicine or slightly many) with hydrochloric solution, unnecessary HCl is removed in adding crystal seed or decompression (35 ℃) behind the certain hour, crystallization, promptly get the hydrochlorate of benzimidazole medicine, be referred to as hydrochloric acid benzimidazole medicine in the present invention.
Preferred manufacturing procedure is: above-mentioned four kinds of benzimidazole medicines are added hydrochloric acid/ethanol (3: 7) liquid by 1: 1.2～1.4 (W/V), and stirring and evenly mixing reacted about 10 minutes, get final product a large amount of crystallizes, filter, get solids, filtrate decompression boils off solvent, and remaining hydrochloric acid benzimidazole medicine is separated out from mother solution, takes out, drying merges drying with the solids that obtains for the first time, pulverize, cross 60 mesh sieves, sealing is deposited, promptly.
If the hydrochloric acid benzimidazole medicine of above-mentioned gained is used to prepare injectable powder (injectable powder), need in case of necessity to wash 2～3 times with cold ethanol, carry out purification process, in case of necessity, need use activated carbon treatment.
Albendazole oxide monohydrochloride or oxfendazole chloride can be raw material with albendazole or Phenbendasol respectively also, are scattered in the hydrochloric liquid, add hydrogen peroxide liquid or other oxidant, and oxidation makes.
The invention is characterized in hydrochloric acid benzimidazole anti-parasite medicine is packed with special container, time spent adds dissolution with solvents or is partly dissolved or is prepared into uniform suspension, be used for the controlling animal parasites disease, but drug administration by injection under the percutaneous, but also per os perfusion.This agent is easy to use, and convenient transportation is deposited conveniently, and good stability can change administering mode and dosage according to different animals, different purposes.
Summary of the invention
The powder of hydrochloric benzimidazole anti-parasite medicine of the present invention or injectable powder, it is characterized in that hydrochloric acid benzimidazole drug powder is added dissolution with solvents or dispersion in use, be used for the parazoon control, can adopt subcutaneous injection, but also intramuscular injection also can orally use.
Described hydrochloric acid benzimidazole medicine comprises: hydrochloric acid albendazole, Albendazole oxide monohydrochloride, hydrochloric acid Phenbendasol, oxfendazole chloride.
The injectable powder of hydrochloric albendazole sulfoxide consists of: Albendazole oxide monohydrochloride 20～100% (W/W), and all the other are filler, auxiliary agent, local analgesia agent or albendazole sulfoxide micropowder (fineness is less than 100 μ m); The injectable powder of hydrochloric albendazole sulfoxide is applicable to animal nematicide, trematodiasis and taeniasis control, injectable powder with hydrochloric albendazole sulfoxide during use mixes with liquid dispersion medium, after treating injectable powder dissolving or being partly dissolved, under animal skins or intramuscular injection, but also oral administration, dosage is 1～30mg albendazole sulfoxide/kg body weight.
Described being used to disperses the liquid dispersion medium of Albendazole oxide monohydrochloride injectable powder to comprise: water, contain 0.5～3% lignocaine or tetracaine or Anuject, 1,2-propylene glycol, glycerol, Polyethylene Glycol, formal glycerine, but they more than one use together, also can use with N-methyl-ketopyrrolidine or dimethyl acetylamide; Being used to disperse the liquid of hydrochloric albendazole sulfoxide injectable powder can also be vegetable oil or oleic acid or oleyl alcohol or ethyl oleate or other esters that is formed by propylene glycol or glycerol.
Described local analgesia agent comprises: the local analgesia agent of procaine hydrochloride, lidocaine hydrochloride or solid states such as tetracaine hydrochloride or chlorobutanol; Preferred procaine hydrochloride, lignocaine, its addition is 1～20% (W/W) in injectable powder.
Preferably be used to disperse the liquid dispersion medium of Albendazole oxide monohydrochloride injectable powder to comprise: water, contain 2% lignocaine or Anuject, 1,2-propylene glycol, formal glycerine, or they more than one use together.
Consisting of of hydrochloric albendazole or oxfendazole chloride's injectable powder: hydrochloric acid albendazole or oxfendazole chloride 20～100% (W/W), all the other are filler, auxiliary agent; This agent is applicable to animal nematicide, trematodiasis and taeniasis control, injectable powder with hydrochloric albendazole or oxfendazole chloride during use mixes with liquid dispersion medium, be prepared into liquid, under animal skins or intramuscular injection, or oral administration, dosage is 1～30mg active ingredient amount/kg body weight.
Describedly be used to disperse the liquid dispersion medium of hydrochloric acid albendazole or oxfendazole chloride's injectable powder to comprise: 1,2-propylene glycol, glycerol, Macrogol 200～600, formal glycerine, but they more than one use together, also can use with N-methyl-ketopyrrolidine or dimethyl acetylamide.
Preferably being used to disperse the liquid dispersion medium of hydrochloric acid albendazole or oxfendazole chloride's injectable powder is 1, and use is united in 2-propylene glycol, formal glycerine or they.
The preparation method of the injectable powder of hydrochloric benzimidazole medicine and application process are: the injectable powder of hydrochloric benzimidazole medicine is sub-packed in the container A, the liquid dispersion medium of dissolving or dispersion hydrochloric acid benzimidazole medicine injectable powder is sub-packed in the container B, during use the liquid dispersion medium in the container B is injected in the container A, shake, after making it solids dissolving or being partly dissolved and being uniformly dispersed, can be to animal injection or oral administration, dosage (calculating by active ingredient) is 0.5～30mg/kg b.w..
The present invention selects Albendazole oxide monohydrochloride and albendazole sulfoxide micropowder to prepare powder or injectable powder especially, add the molten suspension that entry or other dissolution with solvents are prepared into the Albendazole oxide monohydrochloride solution of 1～35% (W/V) or contain albendazole sulfoxide 20-40% during use, the special water, 1 of selecting, 2-propylene glycol, formal glycerine or 1,2-propylene glycol/formal glycerine dissolving Albendazole oxide monohydrochloride.This liquid is used for parazoon control, and injectable uses, can be directly oral, and gavage or drink after also can converting water, also can be mixed in feed in the feedstuff.Described molten suspension, be that a part of albendazole sulfoxide is to exist with dissolved state in the liquid, part albendazole sulfoxide is to exist with graininess, the albendazole sulfoxide of dissolved state plays quick-acting effects, the albendazole sulfoxide of graininess plays slow releasing function, the immediate release section of forming preparation is an Albendazole oxide monohydrochloride, the slow-released part of forming preparation is an albendazole sulfoxide, can add cetomacrogol 1000～20000 (PEG1000～20000) in the preparation, polyvinylpyrrolidone (PVP) or carboxymethyl cellulose (CMC), their main rising in preparation are disperseed, the suspending effect.
In the preparation of hydrochloric benzimidazole anthelmintic drug of the present invention, also can add Macrolide anthelmintic drug (comprising: avilamycin abamectin, ivermectin ivermectin, road draw rhzomorph doramectin, moxidectin moxidectin, Ai Purui rhzomorph eprinomectin, 4"-Deoxy-4"-epi-methylaminoavermectin B1 emamectin), form compound recipe injectable powder or oral powder, their content in preparation is: 0.2～15% (W/V).After preferably Macrolide anthelmintic and water-solubility carrier (as molecular weight greater than 1000 Polyethylene Glycol, polyvinylpyrrolidone, polyvinyl alcohol, sugar alcohols etc.) being made solid dispersion, be mixed with hydrochloric acid benzimidazole anthelmintic drug, be prepared into powder or injectable powder, during use, add disperse medium, make it to be dispersed into suspension, per os or subcutaneous injection administration.
Albendazole oxide monohydrochloride also can be combined into compound preparation with levamisole hydrochloride, or is combined into ternary compound recipe injectable powder with levamisole hydrochloride/Macrolide anthelmintic drug, but the administration of said preparation subcutaneous injection also can orally use.During use, add after water or other liquid dispersion again to animal injection or oral.The effect of killing of this compound preparation antagonistic drug nematodes is very outstanding.
Described Macrolide anthelmintic drug preferably exists with solid dispersion state or microcapsule or microsphere state in above-described preparation, forms to contain the solid dispersion of Macrolide anthelmintic drug or the carrier material of microcapsule or microsphere comprises: polyvinylpyrrolidone, molecular weight is greater than 1000 Polyethylene Glycol, ethyl cellulose, polylactic acid, Acetic acid, hydroxy-, bimol. cyclic ester/lactide, gelatin, arabic gum, alginate, protide is (as albumin, zein, egg albumen, the calf casein), starch based is (as hetastarch, carboxymethyl starch, maleic acid esterification starch-acrylic copolymer), carboxymethyl cellulose salt, O-2-methyl cellulose acetate, methylcellulose, hypromellose, polyester, the polymer anhydride.More than these carrier materials all are commercial goods, their physicochemical property and biological characteristics are all on the books in general pharmaceutics book.
The specific embodiment
Demonstrate injectable powder of the present invention below, but example does not limit claim scope of the present invention.
Example 1, preparation contain the injectable powder of 20% Albendazole oxide monohydrochloride injection
Get Albendazole oxide monohydrochloride 100g, the volume of packing into is that sealing is deposited in the tool plug plastic bag of 500ml.During use, in plastic bag, inject sterilized water or normal saline or 2% lignocaine solution 450ml, shake to Albendazole oxide monohydrochloride and dissolve fully, can use (being difficult for putting for a long time).Be used for Hepar Bovis seu Bubali sheet trematodiasis, nematicide, taeniasis control, this agent of shot 1-1.5ml/40～60kg.b.w.As use this agent oral administration, get final product with eliminating cold for resuscitation water dissolution hydrochloric acid albendazole sulfoxide.
Example 2, preparation contain the injectable powder of 20% oxfendazole chloride's injection
Get oxfendazole chloride 100g, in the tool plug plastic bag of the 500ml that packs into, sealing is deposited.Other gets 450ml 1, and 2-propylene glycol/formal glycerine (1: 1) cosolvent is packed in another plastic bag (can by loading onto injection needle), and sealing is deposited.
Using method: during use, with 450ml 1,2-propylene glycol/formal glycerine (1: 1) cosolvent all is injected in the dress oxfendazole chloride plastic bag, shakes, and the oxfendazole chloride is all dissolved.Be communicated with continuous injector afterwards, can use.Be used for cattle, sheep or the control of pig parasitic worm, 50～70 kg body weight are injected this agent 1-1.2ml and are got final product.
Example 3, preparation contain the injectable powder of 30% Albendazole oxide monohydrochloride injection
The 30g Albendazole oxide monohydrochloride is sub-packed in the 100ml plastic bottle, seals, promptly get the injectable powder that to prepare 30% Albendazole oxide monohydrochloride solution with plug.Other gets 76ml 1, and 2-propylene glycol/formal glycerine (2: 1) solvent is encased in (bag has the interface that is connected with injection needle) in the 80ml plastic bag.During use, the plastic bag interface of dress solvent is cut off, syringe needle in the connection, with 1 in the bag, 2-propylene glycol/formal glycerine all is injected in the plastic bottle of dress Albendazole oxide monohydrochloride, shakes, and makes it dissolving, can use.Be used for cattle, sheep or the control of pig parasitic worm, 60 kg body weight are injected this liquid 1ml.
Example 4, preparation contain the injectable powder of albendazole sulfoxide 40% molten suspension
With Albendazole oxide monohydrochloride and albendazole sulfoxide micropowder mixing, 100ml bottle packing 40g added 70ml water during use, shake in 1: 1 ratio, when treating to soak into fully, can use subcutaneous injection, 50 kg body weight are injected this agent 1ml, and this agent promptly has quick-acting effects, have slow releasing function again.
Example 5, preparation contain the powder or the injectable powder of albendazole sulfoxide and ivermectin
Ivermectin is become solid dispersion with cetomacrogol 1000～20000 or with polyvinylpyrrolidone or with other water-solubility carrier material preparation, be mixed with Albendazole oxide monohydrochloride afterwards and be prepared into powder or injectable powder, or the solid preparation of other state, during use injectable powder converted water or water for injection, be prepared into certain density suspension, injection or oral administration.
Example 6, preparation contain the powder or the injectable powder of albendazole sulfoxide, ivermectin and levamisole hydrochloride
Ivermectin is become solid dispersion with cetomacrogol 1000～20000 or with polyvinylpyrrolidone or with other water-solubility carrier material preparation, be mixed with Albendazole oxide monohydrochloride and levamisole hydrochloride afterwards, be prepared into the solid preparation of powder or injectable powder or other state, during use preparation converted water or water for injection, be prepared into certain density suspension, injection or oral administration.
Example 7, contain the injectable powder of 90% Albendazole oxide monohydrochloride
Get 18g Albendazole oxide monohydrochloride (crossing 80 mesh sieves), add 2g procaine hydrochloride powder, mixing is sub-packed in the cillin bottle of 100ml, seals bottleneck with plug.Purposes and using method: this agent is used for the control of animal nematicide, trematodiasis, taeniasis.During use, in bottle, add the 82ml sterile water for injection, sway, treat can use after solid drugs dissolves substantially, when being used for pig, cattle, sheep parasitic worm disease, subcutaneous or intramuscular injection 7mg Albendazole oxide monohydrochloride/kg body weight.
The pharmacokinetics test of example 8, example 7
This example is the pharmacokinetics test of example 7.Experiment divides two groups: the 1st group, laboratory animal are totally 5 of sheep, and subcutaneous injection example 7 preparations, dosage are 7mg/kg b.w., and albendazole sulfoxide content (mg/ml) in the blood plasma is measured in the blood sampling of administration posterior vein; The 2nd group, oral 10% albendazole suspension, laboratory animal is 5 sheep, and dosage is 7mg/kg b.w., and albendazole sulfoxide content (mg/ml) result such as following table in the blood plasma measured in the blood sampling of administration posterior vein:
| Time (h) | 0.5??????1????????4????????10???????15???????25???????40??????50 |
| The 1st group | 1.82?????2.45?????2.65?????2.13?????1.86?????1.53?????0.82????0.31 |
| The 2nd group | 0.78?????1.46?????1.71?????1.64?????2.13?????1.97?????1.25????0.56 |
Numeral is the meansigma methods of 5 sheep in the ※ table
Example 9, contain the injectable powder of ivermectin and Albendazole oxide monohydrochloride
(1), preparation is formed: Albendazole oxide monohydrochloride micropowder (less than 75 μ m) 61.5% (W/W), the solid dispersion 35% (W/W) of ivermectin/cetomacrogol 1000 0 (1: 3) combination, procaine hydrochloride 3.5% (W/W).Every bottle of this injectable powder of packing 50g.
(2), using method: during use, in the cillin bottle of the injectable powder that contains above component, inject water for injection 80ml, be prepared into hydrochloric albendazole sulfoxide 25% (W/V), the suspension of ivermectin 3.65% (W/V) is given sheep or Corii Bovis seu Bubali this agent of injection 1ml/40～50kg.b.w. down, sheep, cattle parasitic nematode, distoma hepaticum, part cestode and epizoa parasites such as (demodicid mite, Ticks, sucking louse, fly larvae) there is 95% above repelling and killing efficacy, and a drug, killing activity and can keep (effect of ivermectin) more than 40 days epizoa and nematicide.
Example 10,
(1) preparation is formed: Albendazole oxide monohydrochloride 70% (W/W), Macrolide anthelmintic drug 3%, all the other are soluble starch or/and cetomacrogol 1000～20000, and in preparation, Macrolide anthelmintic drug and soluble starch or Polyethylene Glycol are formed the solid dispersion state and existed;
(2) using method: during use, water is mixed with this powder, be prepared into and contain Macrolide anthelmintic drug 0.2～0.4% (W/V), the suspension of hydrochloric albendazole sulfoxide 5～9% (W/V), this suspension is used for the sick and ectoparasite disease control of animal parasitic worm, per os gavages, and dosage is Albendazole oxide monohydrochloride 5～9mg/kg b.w., Macrolide anthelmintic 0.2～0.4mg/kg b.w..
Claims (10)
1, a kind of powder of hydrochloric benzimidazole anti-parasite medicine or injectable powder, it is characterized in that hydrochloric acid benzimidazole medicine is added dissolution with solvents or dispersion in use, be used for the animal parasitosis control, can adopt subcutaneous injection, but also intramuscular injection also can orally use.
2, by described powder of claim 1 or injectable powder, it is characterized in that described hydrochloric acid benzimidazole medicine comprises: hydrochloric acid albendazole, Albendazole oxide monohydrochloride, hydrochloric acid Phenbendasol, oxfendazole chloride.
3, described by claim 1 and 2, it is characterized in that: (1) is prepared into injectable powder with described Albendazole oxide monohydrochloride, the content of Albendazole oxide monohydrochloride is 20～100% (W/W) in injectable powder, and all the other are filler, auxiliary agent, local analgesia agent or albendazole sulfoxide micropowder (fineness is less than 100 μ m); (2) this agent is applicable to animal nematicide, trematodiasis and taeniasis control, injectable powder with hydrochloric albendazole sulfoxide during use mixes with liquid dispersion medium, after treating injectable powder dissolving or homodisperse, through animal subcutaneous injection or administered intramuscular, but also oral administration, dosage is 1～30mg albendazole sulfoxide/kg body weight.
4, by the described injectable powder of claim 3, it is characterized in that described being used to disperse the liquid dispersion medium of Albendazole oxide monohydrochloride injectable powder to comprise: water, contain 0.5～3% lignocaine or tetracaine or Anuject, 1,2-propylene glycol, glycerol, Macrogol 200～600, formal glycerine, but they more than one use together, also can use with dimethyl acetylamide or N-methyl-ketopyrrolidine; Being used to disperse the liquid of hydrochloric albendazole sulfoxide injectable powder can also be vegetable oil or oleic acid or oleyl alcohol or ethyl oleate or other esters that is formed by propylene glycol or glycerol.
5, described by claim 1 and 2, it is characterized in that: (1) is prepared into injectable powder with described hydrochloric acid albendazole or oxfendazole chloride, hydrochloric acid albendazole or oxfendazole chloride's content is 20～100% (W/W) in injectable powder, and all the other are filler, auxiliary agent; (2) this agent is applicable to animal nematicide, trematodiasis and taeniasis control, during use with hydrochloric albendazole or oxfendazole chloride's injectable powder and liquid dispersion medium (as 1,2-propylene glycol, glycerol, Macrogol 200～600, formal glycerine, but they more than one use together, also can use with N-methyl-ketopyrrolidine or dimethyl acetylamide) mix, be prepared into liquid, under animal skins or administered intramuscular, or oral administration, dosage is 1～30mg active ingredient amount/kg body weight.
6, described by claim 1～5, it is characterized in that in the injectable powder or powder of described hydrochloric benzimidazole anthelmintic drug, also can add the Macrolide anthelmintic drug (comprising: avilamycin abamectin, ivermectin ivermectin, the road draws rhzomorph doramectin, moxidectin moxidectin, Ai Purui rhzomorph eprinomectin, 4"-Deoxy-4"-epi-methylaminoavermectin B1 emamectin) or levamisole hydrochloride or Macrolide anthelmintic drug and levamisole hydrochloride, form binary or ternary compound recipe injectable powder or oral powder, the content of Macrolide anthelmintic drug is 0～15% (W/W) in compound preparation, the content of levamisole hydrochloride in preparation is 0～60% (W/W), Albendazole oxide monohydrochloride 30～70%, all the other are carrier material, auxiliary agents such as local analgesia agent.
7,, it is characterized in that described compound recipe injectable powder or oral powder are formed and using method is by the described preparation of claim 6:
(1) preparation is formed: a, Albendazole oxide monohydrochloride 40～70% (W/W); B, Macrolide anthelmintic drug 3～15% (W/W); C, procaine hydrochloride 0～8% (W/W); D, levamisole hydrochloride 0～50% (W/W); E, molecular weight are greater than 1000 Polyethylene Glycol or polyvinylpyrrolidone to 100% (W/W).
(2) using method: during use this injectable powder or powder are mixed with water or water for injection, preparation or suspension, oral or drug administration by injection, be used for the control of animal anthelmintic and ectoparasite disease, dosage is: albendazole sulfoxide 1～30mg/kg b.w, ivermectin 0.2～2mg/kg b.w, levamisole hydrochloride 2～15mg/kgb.w..
8, by claim 6 or 7 or described preparation, it is characterized in that described Macrolide anthelmintic drug can solid dispersion in described preparation or microcapsule or microsphere state exist, form and contain the solid dispersion of Macrolide anthelmintic drug or the carrier material of microcapsule or microsphere comprises: polyvinylpyrrolidone, molecular weight is greater than 1000 Polyethylene Glycol, ethyl cellulose, polylactic acid, Acetic acid, hydroxy-, bimol. cyclic ester/lactide, gelatin, arabic gum, alginate, protide is (as albumin, zein, egg albumen, the calf casein), starch based is (as hetastarch, carboxymethyl starch, maleic acid esterification starch-acrylic copolymer), carboxymethyl cellulose salt, O-2-methyl cellulose acetate, methylcellulose, hypromellose, polyester, the polymer anhydride.
9, by claim 6 or 7 described preparations, it is characterized in that described compound preparation is formed and using method is as follows: (1) preparation is formed: a, Albendazole oxide monohydrochloride micropowder 57～65% (W/W), b, Macrolide anthelmintic drug/molecular weight are greater than 1000 the Polyethylene Glycol or the solid dispersion 20～40% (W/W) of polyvinylpyrrolidone (1: 2～4) combination, c, procaine hydrochloride 3～6% (W/W); (2) using method: during use, water for injection is mixed with injectable powder, be prepared into hydrochloric albendazole sulfoxide 20～35% (W/V), contain the liquid of Macrolide anthelmintic drug 1～5% (W/V), subcutaneous injection, be used for the control of animal parasitic worm disease and ectoparasite disease, dosage is Albendazole oxide monohydrochloride 5～15mg/kg b.w., Macrolide anthelmintic drug 0.4～1.5mg/kg b.w..
10,, it is characterized in that described compound preparation is formed and using method is as follows by claim 6 or 7 described preparations:
(1) preparation is formed: Albendazole oxide monohydrochloride 70% (W/W), Macrolide anthelmintic drug 3%, all the other are that soluble starch is or/and cetomacrogol 1000～20000; In preparation, the Macrolide anthelmintic drug can be formed the solid dispersion state with soluble starch or Polyethylene Glycol and exist;
(2) using method: during use, water is mixed with this powder, be prepared into the suspension that contains Macrolide anthelmintic drug 0.2～0.4% (W/V), hydrochloric albendazole sulfoxide 5～9% (W/V), this suspension is used for the sick and ectoparasite disease control of animal parasitic worm, per os gavages, dosage is Albendazole oxide monohydrochloride 5～9mg/kg b.w., Macrolide anthelmintic 0.2～0.4mg/kg b.w..
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410006428 CN1582925A (en) | 2003-08-19 | 2004-03-04 | Powder injection of benzimidazole hydrochloride, etc. for animals |
| PCT/CN2004/001049 WO2005084688A1 (en) | 2004-03-04 | 2004-09-16 | An injection power containing vermifuge |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN03153729.4 | 2003-08-19 | ||
| CN03153729 | 2003-08-19 | ||
| CN 200410006428 CN1582925A (en) | 2003-08-19 | 2004-03-04 | Powder injection of benzimidazole hydrochloride, etc. for animals |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1582925A true CN1582925A (en) | 2005-02-23 |
Family
ID=34621015
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200410006428 Pending CN1582925A (en) | 2003-08-19 | 2004-03-04 | Powder injection of benzimidazole hydrochloride, etc. for animals |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1582925A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008075984A2 (en) * | 2006-12-21 | 2008-06-26 | Bomac Research Limited | Tablet formulation including macrocyclic lactone and levamisole anthelmintic agents |
| CN104478808A (en) * | 2014-12-05 | 2015-04-01 | 常州齐晖药业有限公司 | Pharmaceutically acceptable salt of imidazole insectifuge as well as preparation method and application of salt |
| CN105076179A (en) * | 2015-09-04 | 2015-11-25 | 广东中迅农科股份有限公司 | Pesticide composition containing albendazole and iprodione |
| CN112006985A (en) * | 2020-07-30 | 2020-12-01 | 瑞普（天津）生物药业有限公司 | Powder injection diluent and preparation method and application thereof |
-
2004
- 2004-03-04 CN CN 200410006428 patent/CN1582925A/en active Pending
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008075984A2 (en) * | 2006-12-21 | 2008-06-26 | Bomac Research Limited | Tablet formulation including macrocyclic lactone and levamisole anthelmintic agents |
| WO2008075984A3 (en) * | 2006-12-21 | 2008-07-31 | Bomac Research Ltd | Tablet formulation including macrocyclic lactone and levamisole anthelmintic agents |
| CN104478808A (en) * | 2014-12-05 | 2015-04-01 | 常州齐晖药业有限公司 | Pharmaceutically acceptable salt of imidazole insectifuge as well as preparation method and application of salt |
| CN105076179A (en) * | 2015-09-04 | 2015-11-25 | 广东中迅农科股份有限公司 | Pesticide composition containing albendazole and iprodione |
| CN105076179B (en) * | 2015-09-04 | 2018-05-18 | 广东中迅农科股份有限公司 | A kind of composition pesticide containing rosickyite azoles and iprodione |
| CN112006985A (en) * | 2020-07-30 | 2020-12-01 | 瑞普（天津）生物药业有限公司 | Powder injection diluent and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7666844B2 (en) | Dry mouldable drug formulation | |
| CA2315975C (en) | Phospholipid-coated microcrystals for the sustained release of pharmacologically active compounds and methods of their manufacture and use | |
| WO2011150481A1 (en) | Nanoparticulate composition containing antibiotics for intramammary administration in animals | |
| CN1686117A (en) | Application of levoornidazole in preparation of anti anaerobic bacteria infection medicine | |
| AU2017263253B2 (en) | Drug delivery system for the delivery of antiviral agents | |
| JP2007314542A (en) | Sulfurpentafluorophenylpyrazole for controlling ectoparasitic infestation | |
| TWI433691B (en) | Benzimidazole non-aqueous compositions | |
| CN107773554A (en) | A kind of ivermectin slow-releasing microcapsule and its preparation method and application | |
| CN103830170B (en) | Ivermectin is at body gel injection and preparation method thereof | |
| CN1582925A (en) | Powder injection of benzimidazole hydrochloride, etc. for animals | |
| CN1698637A (en) | Powder injection of macrolides or N-phenyl pyrazoles deworming drug | |
| CN111514157A (en) | Application of composition in preparation of veterinary anti-parasitic drug, veterinary anti-parasitic transdermal solution and preparation method thereof | |
| AU2009245834B2 (en) | Benzimidazole anthelmintic compositions | |
| CN1572302A (en) | Application of avermectin containing parasite resistant pharmaceutical solid dispersion | |
| CN1170523C (en) | Sustained-release drug formulations for implantation | |
| CN1500492A (en) | Veterinary antiparasite suspension injection | |
| CN1698636A (en) | Mixing method of antiparasitic preparation for animals | |
| AU2013201479B2 (en) | Long Acting Compositions | |
| CN1608618A (en) | Veterinary medicine injection containing chlorocyaniosaliamine or its sodium salt | |
| CZ20031421A3 (en) | Stable pharmaceutical form of a medicament against cancer | |
| KR100645268B1 (en) | Pharmaceutical composition for animal drug | |
| CN1850080A (en) | Oral dispersion domperidone coutrolled-release gel and its preparing method | |
| CN1666739A (en) | Application of Silibinin or its salts in preparation of medicine for treating coronary heart disease or strengthening the effect of coronary heart disease treatment | |
| EP2934524B1 (en) | Penethamate veterinary injectable formulations | |
| NZ608177A (en) | Long acting compositions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |